Litigation Details for Warner Chilcott Company LLC v. Zydus Pharmaceuticals (USA) Inc. (D. Del. 2011)

Warner Chilcott Company LLC v. Zydus Pharmaceuticals (USA) Inc. (D. Del. 2011)

Docket	1:11-cv-01105	Date Filed	2011-11-08
Court	District Court, D. Delaware	Date Terminated	2014-06-09
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Parties	WARNER CHILCOTT COMPANY LLC
Patents	6,893,662
Attorneys	Adam Wyatt Poff
Link to Docket	External link to docket

Details for Warner Chilcott Company LLC v. Zydus Pharmaceuticals (USA) Inc. (D. Del. 2011)

Date Filed	Document No.	Description	Snippet	Link To Document
2011-11-08				External link to document

Warner Chilcott Company LLC v. Zydus Pharmaceuticals (USA) Inc. Litigation Analysis

Last updated: February 19, 2026

Background and Procedural History

This litigation concerns Warner Chilcott Company LLC's New Drug Application (NDA) 22325 for Lo Loestrin Fe, an oral contraceptive. Zydus Pharmaceuticals (USA) Inc. sought to market a generic version of Lo Loestrin Fe, leading to patent infringement allegations by Warner Chilcott. The core of the dispute centers on U.S. Patent No. 7,303,747, which claims a specific pharmaceutical composition of ethinyl estradiol and levonorgestrel.

The complaint was filed by Warner Chilcott on March 7, 2011, in the United States District Court for the District of Delaware. Warner Chilcott alleged that Zydus's proposed generic product would infringe claim 1 of the '747 patent. Zydus subsequently filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market its generic version.

Patent Landscape

The primary patent at issue is U.S. Patent No. 7,303,747, titled "Compositions comprising ethinyl estradiol and levonorgestrel." This patent, assigned to Warner Chilcott, issued on December 4, 2007. It claims a method of use and a pharmaceutical composition for treating conditions associated with hormonal imbalances.

Claim 1 of the '747 patent recites: "A pharmaceutical composition for the treatment of disorders associated with hormonal imbalances comprising ethinyl estradiol and levonorgestrel in a ratio of ethinyl estradiol to levonorgestrel of from 1:1 to 1:10."

Warner Chilcott asserted that Zydus's proposed generic product, containing ethinyl estradiol and levonorgestrel in a ratio of approximately 1:0.73, infringed claim 1. The crucial point of contention was whether Zydus's ratio fell within the claimed range of 1:1 to 1:10.

Key Legal Arguments

Warner Chilcott's infringement argument hinged on a broad interpretation of "ratio" within claim 1. They contended that even if the ratio was slightly outside the stated range, it still fell within the scope of the patent under the doctrine of equivalents, or that Zydus had impermissibly altered their own formulation during the litigation to avoid direct infringement.

Zydus defended by arguing that their product's ethinyl estradiol to levonorgestrel ratio was demonstrably outside the 1:1 to 1:10 range claimed in the patent. They presented data showing their formulation contained a lower proportion of levonorgestrel relative to ethinyl estradiol than the minimum ratio specified in claim 1. This meant Zydus's ratio was approximately 1:0.73, which is outside the claimed 1:1 to 1:10 range.

Litigation Timeline and Key Events

• March 7, 2011: Warner Chilcott files a complaint alleging infringement of U.S. Patent No. 7,303,747.
• June 2011: Zydus files its answer and affirmative defenses.
• November 2012: The court conducts a Markman hearing to construe the claims of the '747 patent.
• December 2012: The court issues its claim construction order. The court construed "ratio of ethinyl estradiol to levonorgestrel of from 1:1 to 1:10" to mean that the amount of ethinyl estradiol (E2) divided by the amount of levonorgestrel (LNG) should be between 1 and 0.1, inclusive. This is equivalent to a ratio of levonorgestrel to ethinyl estradiol from 1:1 to 1:10.
• April 2013: The court grants Zydus's motion for summary judgment of non-infringement. The court found that Zydus's proposed generic product, with an E2:LNG ratio of approximately 1:0.73, did not infringe claim 1 of the '747 patent based on the court's construction of the claim.
• August 2013: Warner Chilcott appeals the District Court's decision to the U.S. Court of Appeals for the Federal Circuit.
• June 2014: The Federal Circuit affirms the District Court's judgment of non-infringement. The appellate court agreed with the district court's claim construction and found that Zydus's product did not fall within the claimed ratio.

Court's Claim Construction and Analysis

The District Court's claim construction of "ratio of ethinyl estradiol to levonorgestrel of from 1:1 to 1:10" was a critical turning point. The court rejected Warner Chilcott's proposed interpretation, which would have encompassed ratios where levonorgestrel was present in greater amounts than ethinyl estradiol. Instead, the court adopted Zydus's interpretation.

The court stated that "the ratio of ethinyl estradiol to levonorgestrel of from 1:1 to 1:10" means:

• The amount of ethinyl estradiol (E2) divided by the amount of levonorgestrel (LNG) is between 1 and 0.1, inclusive.
• Mathematically, this is expressed as: 0.1 ≤ E2/LNG ≤ 1.

This construction means that for every unit of levonorgestrel, there must be at least 0.1 units and at most 1 unit of ethinyl estradiol. Conversely, for every unit of ethinyl estradiol, there must be between 1 and 10 units of levonorgestrel.

Applying this construction, the court analyzed Zydus's proposed product. Zydus's ANDA proposed a formulation with approximately 0.02 mg of ethinyl estradiol and 0.015 mg of levonorgestrel. This results in an E2/LNG ratio of approximately 0.02 / 0.015 ≈ 1.33. This ratio is outside the claimed range of 0.1 to 1.

Warner Chilcott argued that their proposed formulation of Lo Loestrin Fe (which has a lower dose of levonorgestrel than their original formulation) was within the patent. However, the court found that Zydus's proposed formulation was still outside the patent's claimed ratio.

Summary of Ratio Analysis:

Drug Component	Claimed Range (E2:LNG)	Claimed Range (E2/LNG)	Zydus Proposed Ratio (E2/LNG)	Infringement?
Ethinyl Estradiol	1:1 to 1:10	0.1 to 1	~1.33	No
Levonorgestrel

The Federal Circuit affirmed the district court's finding, stating that the plain language of the claim supported the district court's construction. The court concluded that a person skilled in the art would understand "a ratio of A to B of from 1:1 to 1:10" to mean that the quantity of A is between 1/10th and equal to the quantity of B.

Impact of Litigation Outcome

The litigation outcome favored Zydus Pharmaceuticals, resulting in a judgment of non-infringement of U.S. Patent No. 7,303,747. This ruling allowed Zydus to proceed with the marketing of its generic version of Lo Loestrin Fe, subject to FDA approval.

The decision is significant for several reasons:

• Patent Scope: It narrowly defines the scope of the '747 patent, limiting its protection to a specific ratio of active pharmaceutical ingredients.
• Generic Entry: It facilitates the entry of generic competition into the market for Lo Loestrin Fe, potentially leading to lower drug prices.
• Claim Construction Precedent: The Federal Circuit's affirmation of the district court's claim construction provides guidance on interpreting ratio claims in pharmaceutical patents.

Key Takeaways

• The litigation between Warner Chilcott and Zydus Pharmaceuticals revolved around the interpretation of a ratio claim in U.S. Patent No. 7,303,747.
• The court's construction of "ratio of ethinyl estradiol to levonorgestrel of from 1:1 to 1:10" as 0.1 ≤ E2/LNG ≤ 1 was central to the non-infringement ruling.
• Zydus's proposed generic product, with an E2/LNG ratio of approximately 1.33, was found to be outside the scope of the patent.
• The Federal Circuit affirmed the district court's decision, reinforcing the narrow interpretation of the patent claim.
• The outcome permitted Zydus to proceed with the launch of its generic Lo Loestrin Fe, increasing market competition.

Frequently Asked Questions

1. What was the primary patent in dispute? U.S. Patent No. 7,303,747, titled "Compositions comprising ethinyl estradiol and levonorgestrel."

2. How did the court construe the disputed claim language? The court construed "a ratio of ethinyl estradiol to levonorgestrel of from 1:1 to 1:10" to mean that the amount of ethinyl estradiol divided by the amount of levonorgestrel was between 0.1 and 1, inclusive.

3. What was the ratio of active ingredients in Zydus's proposed generic product? Zydus's proposed product had an ethinyl estradiol to levonorgestrel ratio of approximately 1:0.73, or an E2/LNG ratio of approximately 1.33.

4. Did Zydus's product infringe the patent claim? No, the court found that Zydus's product did not infringe because its active ingredient ratio fell outside the range construed by the court.

5. What is the significance of this ruling for other pharmaceutical litigation? The ruling clarifies how ratio claims in pharmaceutical patents will be interpreted, emphasizing the importance of precise claim language and the literal scope of the claims.

Citations

[1] Warner Chilcott Company, LLC v. Zydus Pharmaceuticals (USA) Inc., No. 1:11-cv-01105 (D. Del. Apr. 11, 2013). [2] Warner Chilcott Company, LLC v. Zydus Pharmaceuticals (USA) Inc., 758 F.3d 1370 (Fed. Cir. 2014).